It is extremely important to assess the long-term effects of chemotherapy in patients with acute myeloid leukemia (AML); however, with the knowledge of minimal residual disease, it is understood that not all malignant clones can be seen under the microscope. In this interview, Felicitas Thol, MD, of Hannover Medical School, Hannover, Germany, discusses the importance of using novel techniques when observing remission in patients. Although challenging compared to other diseases, such as chronic myeloid leukemia (CML), Dr Thol suggests a more individualized and sensitive approach should be taken due to the complex nature of AML. This interview was held at the American Society of Hematology (ASH) Annual Meeting 2017 in Atlanta, GA.
Novel methods to assess the effectiveness of chemotherapy in AML patients: MRD
